Prenetics Global Limited - Class A Ordinary Share (PRE)
16.76
-0.62 (-3.57%)
NASDAQ · Last Trade: Oct 26th, 3:12 AM EDT
Detailed Quote
Previous Close
17.38
Open
17.49
Bid
16.50
Ask
17.80
Day's Range
16.46 - 17.99
52 Week Range
3.095 - 17.99
Volume
185,814
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
127,352
Chart
About Prenetics Global Limited - Class A Ordinary Share (PRE)
Prenetics Global Limited is a biotechnology company that specializes in providing advanced genetic testing and health insights. Through its innovative platform, the company offers a range of diagnostic solutions that empower individuals and healthcare professionals to make informed decisions regarding genetic health, chronic disease risk, and personalized medical care. Prenetics aims to enhance preventive healthcare by making genetic testing accessible and actionable, leveraging cutting-edge technology and data analytics to support wellness and disease management for its users. Read More
CHARLOTTE, N.C., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (“Prenetics” or the “Company”), a leading health sciences company, today announced that it has commenced a public offering of shares of its Class A Ordinary Shares (or prefunded warrants in lieu thereof) and common warrants (the “Offering”). The Company will allocate proceeds from the offering toward the global expansion of IM8, driven by its explosive growth, and the strategic accumulation of Bitcoin (BTC) as part of its pioneering dual-pronged health and wealth strategy.
CHARLOTTE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, today announced the official completion of its divestment of ACT Genomics Co., Ltd. (“ACT”) to Delta Electronics, Inc. (TWSE:2308). This transaction marks a final step in Prenetics’ strategic exit from the clinical diagnostics sector, enabling the company to dedicate its resources and attention to its rapidly expanding consumer health initiatives.
CHARLOTTE, N.C., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, and its premium supplement brand IM8, co-founded by David Beckham, today extends heartfelt congratulations to global ambassador and shareholder, World No. 1 tennis player Aryna Sabalenka, on successfully defending her singles championship at the 2025 US Open.
CHARLOTTE, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.
CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics”), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited (“ACT Genomics”) to Delta Electronics, Inc. (TWSE: 2308) (“Delta”). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta’s acquisition of up to 100% ACT Genomics’ shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
CHARLOTTE, N.C., June 12, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading health sciences company, today announced unaudited financial results for the first quarter ended March 31, 2025, along with recent business updates.
David Beckham was Joined by Dr. Amy Shah, Dr. Jeremy London, Dr. James DiNicolantonio and Kendal Toole to Reinforce IM8’s Vision for Elite Wellness Accessible to All
CHARLOTTE, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading consumer health sciences company, announced today the Company will participate in the 37th Annual ROTH Conference being held Sunday, March 16th to Tuesday, March 18th at the Laguna Cliffs Marriott Resort in Dana Point, CA.
CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leading genomics and consumer healthcare company, today announced a groundbreaking genomics-based partnership with Humanity Protocol, a decentralized identity verification company. This collaboration leverages Prenetics’ advanced genetic testing capabilities to underpin decentralized identity verification.
The Next Big Thing in Wellness? IM8 Lands in the U.S. with a Star-Studded Launch. David Beckham and a world-class scientific team are putting the focus back on foundational health
